1+1=3? Discussing combination therapies, access, innovation and patient benefit
Event Description
1+1=3? Discussing combination therapies, access, innovation and patient benefit
About the webinar
Access to medicines across Europe has always been high on the policy agendas, recently also in the context of various legislative revisions. While Member States' health systems have established processes for traditional medicines, the ever-advancing landscape of science has given rise to new treatments like combinations, stratified treatments with biomarkers, and gene and cell therapies. Unfortunately, the pathways to the patient don’t always match, and health systems’ budgeting cycles are not set up to absorb innovation.
Patient access is everyone’s responsibility. This Early Bird Debate, organized as a teaser event ahead of the European Cancer Forum on December 5th at the Solvay Library in Brussels, promises an exchange about how health systems should adapt and become better prepared for new innovations, such as combinations therapies.
Join us for the upcoming Early Bird Debate and engage with two experts as they debate why 1+1 does not equal 3!
Moderator:
Duane Schulthess
Managing Director
Vital Transformation
Events of the week
Jobs
EBA - European Biogas Association
SolarPower Europe
Acumen Public Affairs
EUI - European University Institute
Solar Stewardship Initiative
Future Matters
European Energy Forum
Open Future
Bundesverband der Deutschen Volksbanken und Raiffeisenbanken e.V.
EURACTIV News
- EU’s Critical Raw Materials Act will need better financial support, say industry experts [Advocacy Lab Content]
- Swedish hospital bed crisis kills 100 patients, doctors call for Vision Zero
- Bulgarian pharma market gained post-pandemic boost, according to new analysis
- EU’s Borrell to propose suspension of political dialogue with Israel next week
- EPP clinches narrow majority to delay anti-deforestation rules for two years